Presentation (CTI)

OBJECTIVES: To describe the economic savings resulting from the implementation of a rational immunoglobulin use strategy in patients with primary immunodeficiencies.
METHODS: This observational, retrospective study was conducted in a cohort of patients diagnosed with primary immunodeficiency and treated with human immunoglobulin G within a specialized care program during the years 2024 and 2025. A clinical and pharmacotherapeutic follow-up strategy was applied to optimize medication use, aiming to ensure safe, personalized, and cost-effective therapy. A univariate statistical analysis was performed using measures of central tendency, relative frequencies, and cumulative distributions. Data processing was conducted using the R Core Team statistical software, version 4.5.0 (2025).
RESULTS: A total of 80 patients were included, with a mean age of 25 years (SD = 21), of whom 57.5% were male. All patients were receiving treatment with normal human immunoglobulin G. Based on clinical and pharmacotherapeutic monitoring, individualized interventions were implemented by the treating immunologist, including dose adjustments (60.5%), treatment discontinuation (21%), extension of administration intervals (16.1%) and change in drug treatment (2.4%). These measures maintained therapeutic effectiveness and disease control, resulting in an estimated total cost saving of USD 281,702.68.
CONCLUSIONS: The rational use strategy of immunoglobulin therapy in patients with primary immunodeficiencies proved to be clinically effective and economically efficient, contributing to the optimization of healthcare resource utilization.